Compare Amylx Pharmaceuticals Inc (AMLX) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Firy Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Firy Inc. trades at $10.31 (market cap $159.51M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 16.6× Firy Inc.'s market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| AMLX | FIRY | |
|---|---|---|
Market Cap | $2.64B | $159.51M |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $12.45 |
52-Week Low | $7.82 | $2.28 |
Enterprise Value | $2.39B | $103.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
FIRY (formerly Skillz Inc.) trades at $9.98, down 4.77% today, with a bullish technical signal from moving averages. The company shows persistent losses with a -67.38% net margin in 2025 despite an 87.75% gross margin, while revenue declined from $270M in 2022 to $104M in 2025. Recent developments include a legal victory securing $719M and a corporate rebranding to FIRY.
The outlook remains challenging due to sustained negative cash flows and profitability issues, though the legal win provides a potential catalyst. Analyst sentiment is mixed with 60% hold ratings. Key risks include execution on profitability and competitive pressures in mobile gaming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
